Jana L. Dawson

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Adil Daud, Jana L. Dawson, Ronald C. DeConti et al. · Clinical Cancer Research · 2009 · 88 citations · Full text

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Joel G. Turner, Trinayan Kashyap, Jana L. Dawson et al. · Oncotarget · 2016 · 88 citations · Full text

Hematological Malignancy, Tumor Biology, Proteasome Inhibitor Resistance +13

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Joel G. Turner, Jana L. Dawson, Steven Grant et al. · Journal of Hematology & Oncology · 2016 · 81 citations · Full text

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

Joel G. Turner, Douglas C. Marchion, Jana L. Dawson et al. · Cancer Research · 2009 · 80 citations · Full text

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

Joel G. Turner, Jana L. Dawson, Michael F. Emmons et al. · Journal of Cancer · 2013 · 78 citations · Full text

Hematological Malignancy, Tumor Biology, Ex Vivo +15